These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 20858840)

  • 1. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
    Anders CK; Winer EP; Ford JM; Dent R; Silver DP; Sledge GW; Carey LA
    Clin Cancer Res; 2010 Oct; 16(19):4702-10. PubMed ID: 20858840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
    Comen EA; Robson M
    Cancer J; 2010; 16(1):48-52. PubMed ID: 20164690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
    Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
    Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of PARP inhibitors for metastatic breast cancer.
    Irshad S; Ashworth A; Tutt A
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1243-51. PubMed ID: 21916578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
    Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
    Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.
    Comen EA; Robson M
    Oncology (Williston Park); 2010 Jan; 24(1):55-62. PubMed ID: 20187322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducing synthetic lethality using PARP inhibitors.
    Boss DS; Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):192-5. PubMed ID: 20406170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
    Sulai NH; Tan AR
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
    Plummer R
    Breast Cancer Res; 2011 Aug; 13(4):218. PubMed ID: 21884642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
    Curtin NJ; Szabo C
    Mol Aspects Med; 2013 Dec; 34(6):1217-56. PubMed ID: 23370117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
    He JX; Yang CH; Miao ZH
    Acta Pharmacol Sin; 2010 Sep; 31(9):1172-80. PubMed ID: 20676117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research progresses of the PARP inhibitors for the treatment of cancer].
    He YJ; Liu RH; Ning CQ; Yu NF
    Yao Xue Xue Bao; 2013 May; 48(5):655-60. PubMed ID: 23888686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.